• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$132.17 $2.46 (1.90%)

REAL-TIME: Last trade at

Regeneron Pharmaceuticals, Inc...

NASDAQ:REGN

Jump to this page for:

Related Resources

Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet

5/26/2012 by PR Newswire

7 Biotech Stocks to Add to Your Portfolio

5/26/2012 by InvestorPlace

New York Biotechnology Association to Honor Regeneron Founders as Business Leaders of the Year

5/18/2012 by PharmiWeb.com - UK

New York Biotechnology Association to Honor Regeneron Founders as Business Leaders of the Year

5/18/2012 by Business Wire

FDA Advisers Reject Regeneron Pharmaceuticals, Inc. Gout Drug

5/10/2012 by BioSpace

Regeneron Announces Presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference

5/10/2012 by PR Newswire

Critical Alerts For NVIDIA, Ingersoll Rand, Sotheby's, Nuance Communications, and Regeneron Pharmaceuticals Released By InvestorsObserver

5/10/2012 by PR Newswire

Critical Alerts For NVIDIA, Ingersoll Rand, Sotheby's, Nuance Communications, and Regeneron Pharmaceuticals Released By InvestorsObserver

5/10/2012 by StockWatch

Jefferies Trims Target on Regeneron Pharma (REGN) After Arcalyst News, Keeps Buy Rating

5/9/2012 by StreetInsider.com

FDA advisers snub Regeneron drug for gout

5/9/2012 by Fierce Biotech

Regeneron has a conference call hosted by JP Morgan

5/9/2012 by Theflyonthewall.com

Regeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series

5/9/2012 by PR Newswire

Regeneron Dips on Safety Concern Over Gout Treatment [UPDATE]

5/9/2012 by Minyanville

Regeneron And Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection In Japan

5/9/2012 by Pharmaceutical Online

Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection

5/8/2012 by PR Newswire

Regeneron management to meet with Jefferies

5/8/2012 by Theflyonthewall.com

Santen Pharmaceutical Nabs Japanese Co-Promotion Rights to Bayer HealthCare and Regeneron Pharmaceuticals, Inc.'s Eylea

5/8/2012 by BioSpace

Regeneron (REGN), Bayer Report Co-Promotion Agreement for EYLEA in Japan

5/8/2012 by StreetInsider.com

FDA Arthritis Advisory Committee to hold a meeting

5/8/2012 by Theflyonthewall.com

Regeneron, Bayer announce co-promotion agreement with Santen for EYLEA

5/8/2012 by Theflyonthewall.com

FDA queries safety of Regeneron's Arcalyst for gout

5/8/2012 by PharmaTimes - UK

FDA Cites Cancer Risk with Arcalyst, Regeneron’s New Gout Drug

5/7/2012 by NewsInferno

6 Best Biotech Stocks With More Upside Potential

5/7/2012 by Seeking Alpha

Analyzing Noteworthy Insider Trades Last Week In Regeneron, Covidien, And Other Healthcare Stocks

5/7/2012 by Seeking Alpha

6 Stocks To Watch: BRK, YHOO, DIS, REGN, UAL & PSX

5/6/2012 by Forbes

FDA Staff Question Side Effects of Regeneron Pharmaceuticals, Inc. Gout Drug

5/4/2012 by BioSpace

Correction: FDA staff says Arcalyst has "small" benefit in reducing gout flares

5/4/2012 by Theflyonthewall.com

Regeneron weakness a buying opportunity, says Deutsche Bank

5/4/2012 by Theflyonthewall.com

26 Drugs Facing FDA Approval in 2012

5/2/2012 by TheStreet.com

The Eyes Have It? What The CATT Study Means For Regeneron

4/30/2012 by Forbes

Eylea Drives Regeneron to Profit - Analyst Blog

4/27/2012 by Zacks Investment Research

Eylea Drives Regeneron to Profit

4/27/2012 by Zacks Equity Research Analyst Blog

Regeneron target raised to $165 from $135 at ThinkEquity

4/27/2012 by Theflyonthewall.com

Top Analyst Upgrades & Downgrades (AET, AEM, APD, ALU, MDRX, AMZN, AMCC, BIDU, CBG, CTCT, DECK, EBAY, LOGI, PCS, PM, REGN, SNDK, STX, WDC, ZNGA)

4/27/2012 by 24/7 Wall Street

BMO Capital Downgrades Regeneron Pharma (REGN) to Market Perform

4/27/2012 by StreetInsider.com

Sanofi: Strong performance in Q1 2012 including Genzyme contribution

4/27/2012 by PR Newswire

Regeneron downgraded to Market Perform from Outperform at BMO Capital

4/27/2012 by Theflyonthewall.com

Regeneron jumps on 1Q profit and stronger outlook

4/26/2012 by Bioscience Technology

Austerity Pressures AMD Drug Pricing As Avastin Attracts

4/26/2012 by Seeking Alpha

24/7 Wall St. Closing Bell (GD, ABB, HOG, COP, S, ALU, MO, PEP, TLAB, XOM, AET, BMY, BG, JBLU, LIZ, MJN, REGN, SWY, SWC, TASR, UPS, YNDX, NRGY, SPH, LEAP, AKAM)

4/26/2012 by 24/7 Wall Street
See More Articles...